TRCT
PLX icon

Tower Research Capital (TRC)’s Protalix BioTherapeutics PLX Stock Holding History

Tower Research Capital (TRC)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2K Buy
8,669
+3,511
+68% +$7.43K ﹤0.01% 3547
2026
Q1 		$11.2K Sell
5,158
-1,075
-17% -$2.67K ﹤0.01% 3855
2025
Q4 		$11.2K Buy
6,233
+720
+13% +$1.47K ﹤0.01% 3626
2025
Q3 		$12.2K Buy
5,513
+5,386
+4,241% +$8.77K ﹤0.01% 3806
2025
Q2 		$188 Buy
+127
New +$260 ﹤0.01% 5111
2024
Q4 		– Sell
-5,055
Closed -$5.16K – 5929
2024
Q3 		$5.16K Sell
5,055
-12,824
-72% -$13.5K ﹤0.01% 4318
2024
Q2 		$20.9K Buy
17,879
+13,986
+359% +$16.5K ﹤0.01% 3740
2024
Q1 		$4.91K Sell
3,893
-8,039
-67% -$12K ﹤0.01% 4615
2023
Q4 		$21.2K Buy
11,932
+5,179
+77% +$8.05K ﹤0.01% 3610
2023
Q3 		$11.2K Buy
6,753
+4,161
+161% +$7.47K ﹤0.01% 4022
2023
Q2 		$5.18K Buy
2,592
+990
+62% +$2.36K ﹤0.01% 4850
2023
Q1 		$3K Buy
+1,602
New +$2.81K ﹤0.01% 5225
2022
Q2 		– Sell
-6,465
Closed -$7K – 6428
2022
Q1 		$7K Buy
6,465
+6,393
+8,879% +$5.86K ﹤0.01% 4748
2021
Q4 		$0 Buy
+72
New +$75 ﹤0.01% 6465
2021
Q3 		– Sell
-4,658
Closed -$9K – 6071
2021
Q2 		$9K Buy
4,658
+3,570
+328% +$12.3K ﹤0.01% 4444
2021
Q1 		$5K Buy
+1,088
New +$5.07K ﹤0.01% 4682
2015
Q2 		– Sell
-41
Closed -$1K – 4879
2015
Q1 		$1K Sell
41
-102
-71% -$2K ﹤0.01% 4107
2014
Q4 		$3K Sell
143
-103
-42% -$2.21K ﹤0.01% 3134
2014
Q3 		$6K Sell
246
-21
-8% -$605 ﹤0.01% 3176
2014
Q2 		$10K Buy
267
+6
+2% +$242 ﹤0.01% 2372
2014
Q1 		$12K Buy
261
+68
+35% +$3.17K ﹤0.01% 2433
2013
Q4 		$7K Buy
193
+35
+22% +$1.47K ﹤0.01% 3303
2013
Q3 		$7K Buy
158
+119
+305% +$6.11K ﹤0.01% 3452
2013
Q2 		$2K Buy
+39
New +$2.07K ﹤0.01% 3498

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Tower Research Capital (TRC)'s PLX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Protalix BioTherapeutics (PLX) stake by 68% in Q2 2026, buying an estimated $7.43K and bringing the position to 8,669 shares worth $20.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3547.

Tower Research Capital (TRC) first reported a position in PLX in Q2 2013 and has held it in 24 quarters since. The position peaked at $21.2K in Q4 2023. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Tower Research Capital (TRC) held 8,669 shares of Protalix BioTherapeutics worth $20.2K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,511 Protalix BioTherapeutics shares in Q2 2026, an estimated $7.43K.
  • Protalix BioTherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3547 holding.
  • Tower Research Capital (TRC) first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Protalix BioTherapeutics position peaked at $21.2K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.